Search Results

• • 83 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma

  Authors:Paul A. Robertson, Helen J. Ross, and Robert A. FiglinFrom:Annals of Internal Medicine (Vol. 111, Issue 8) Peer-Reviewed

  Oct. 15, 1989265 words Article

   Abstract Only

• Health Related Quality of Life Outcomes in Patients Treated for Metastatic Kidney Cancer: A Pilot Study

  Authors:Mark S. Litwin, Jennifer T. Fine, Frederick Dorey, Robert A. Figlin, and Arie S. BelldegrunFrom:The Journal of Urology (Vol. 157, Issue 5) Peer-Reviewed

  May 199779 words Article

   Abstract Only

• Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

  Authors:Karen L. Reckamp, Marianna Koczywas, Mihaela C. Cristea, Jonathan E. Dowell, He-Jing Wang, Brian K. Gardner, et al.From:Cancer (Vol. 121, Issue 18) Peer-Reviewed

  Sept. 15, 2015 Report

   Citation Only

• Clinical Management of Renal Tumors

  Author:Robert A. FiglinFrom:The New England Journal of Medicine (Vol. 359, Issue 15) Peer-Reviewed

  Oct. 9, 2008 Book review

   Citation Only

• A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

  Authors:Hao Zhang, Dror Berel, Yanping Wang, Ping Li, Neil A. Bhowmick, Robert A. Figlin, et al.From:PLoS ONE (Vol. 8, Issue 1) Peer-Reviewed

  Jan. 22, 20136,664 words Article 1370LAuthor(s): Hao Zhang 1 , Dror Berel 2 , 4 , Yanping Wang 1 , Ping Li 1 , Neil A. Bhowmick 3 , Robert A. Figlin 3 , Hyung L. Kim 1 , 4 , * Introduction Renal cell carcinoma (RCC) is the most common malignancy of...

• Circulating proteins as potential biomarkers of sunitinib and interferon-[alpha] efficacy in treatment-naive patients with metastatic renal cell carcinoma

  Authors:Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, M. Dror Michaelson, et al.From:Cancer Chemotherapy and Pharmacology (Vol. 73, Issue 1) Peer-Reviewed

  Jan. 2014423 words Report

   Abstract Only

• Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma

  Authors:Eric Jonasch, Walter M. Stadler, Ronald M. Bukowski, Teresa G. Hayes, Atul Varadhachary, Rajesh Malik, et al.From:Cancer (Vol. 113, Issue 1) Peer-Reviewed

  July 1, 2008 Clinical report

   Citation Only

• Novel therapeutics for metastatic renal cell carcinoma

  Authors:Thomas E. Hutson and Robert A. FiglinFrom:Cancer (Vol. 115, Issue 10) Peer-Reviewed

  May 15, 2009 Conference notes

   Citation Only

• G250: A carbonic anhydrase IX monoclonal antibody

  Authors:John S. Lam, Allan J. Pantuck, Arie S. Belldegrun, and Robert A. FiglinFrom:Current Oncology Reports (Vol. 7, Issue 2)

  Apr. 2005247 words Article

   Abstract Only

• Cachexia-Like Symptoms Predict a Worse Prognosis in Localized T1 Renal Cell Carcinoma

  Authors:Hyung L. Kim, Ken-Ryu Han, Amnon Zisman, Robert A. Figlin, and Arie S. BelldegrunFrom:The Journal of Urology (Vol. 171, Issue 5) Peer-Reviewed

  May 200495 words Article

   Abstract Only

• Current management of renal cell carcinoma

  Authors:Mitchell H. Sokoloff, Jean B. deKernion, Robert A. Figlin, and Arie BelldegrunFrom:Ca (Vol. 46, Issue 5) Peer-Reviewed

  September-October 1996 Article

   Citation Only

• Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib

  Authors:Avishay Sella, M. Dror Michaelson, Ewa Matczak, Ronit Simantov, Xun Lin, and Robert A. FiglinFrom:Clinical Genitourinary Cancer (Vol. 15, Issue 2) Peer-Reviewed

  Apr. 2017403 words Article

   Abstract Only

• Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

  Authors:David Cella, Mellar P. Davis, Sylvie Negrier, Robert A. Figlin, M. Dror Michaelson, Andrew G. Bushmakin, et al.From:Cancer (Vol. 120, Issue 12) Peer-Reviewed

  June 15, 2014 Report

   Citation Only

• Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC

  Author:Robert A. FiglinFrom:Nature Clinical Practice Oncology (Vol. 5, Issue 10) Peer-Reviewed

  Oct. 20085,771 words Article Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) that is approved for the treatment of advanced renal cell carcinoma. mTOR is unique among antitumor drug targets because it is a convergence...

• Recent advances in the medical treatment of recurrent or metastatic renal cell cancer

  Authors:Rekha A. Kumbla, Robert A. Figlin, and Edwin M. PosadasFrom:Drugs (Vol. 77, Issue 1) Peer-Reviewed

  Jan. 1, 2017 Article

   Citation Only

• Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

  Authors:Robert J. Motzer, Thomas E. Hutson, Gary R. Hudes, Robert A. Figlin, Jean-Francois Martini, Patricia A. English, et al.From:Cancer Chemotherapy and Pharmacology (Vol. 74, Issue 4) Peer-Reviewed

  Oct. 2014450 words Report

   Abstract Only

• Progress and controversies in neoadjuvant therapy

  Authors:Edwin M. Posadas and Robert A. FiglinFrom:Nature Reviews Urology (Vol. 11, Issue 5) Peer-Reviewed

  May 20141,670 words Article 1590LUse of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall...

• Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

  Authors:Jacob J. Adashek, Meghan M. Salgia, Edwin M. Posadas, Robert A. Figlin, and Jun GongFrom:Clinical Genitourinary Cancer (Vol. 17, Issue 3) Peer-Reviewed

  June 2019196 words Author abstract, Rep...

   Abstract Only

• Chemokines as therapeutic targets in renal cell carcinoma

  Authors:Karen L Reckamp, Robert M Strieter, and Robert A FiglinFrom:Expert Review of Anticancer Therapy (Vol. 8, Issue 6) Peer-Reviewed

  June 20085,150 words Article Author(s): Karen L Reckamp [[dagger]] 1 , Robert M Strieter 2 , Robert A Figlin 3 Keywords: angiogenesis; chemokine; metastatic potential; renal cell carcinoma; treatment Increased understanding of the...

• Role of molecular markers in the diagnosis and therapy of renal cell carcinoma

  Authors:John S. Lam, John T. Leppert, Robert A. Figlin, and Arie S. BelldegrunFrom:Urology (Vol. 66, Issue 5) Peer-Reviewed

  Nov. 2005234 words Report

   Abstract Only